Pharmacokinetics & Drug Delivery | Antimicrobial Agents | Gastrointestinal Pharmacology | Methods for Diagnostic & Therapeutic Studies | Liver Failure & Liver Disease | Viral Hepatitis
Maintained viral suppression and excellent safety profile of entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B : a 4-year field practice, multicenter study
Pietro Lampertico*, Mauro Viganò, Roberta Soffredini, Floriana Facchetti, Eliseo Minola, Giuliana Cologni, Marco Rizzi, Osvaldo Fracassetti, Fredy Suter, Serena Zaltron, Andrea Vavassori, Giampiero Carosi, M Puoti, Elena Angeli, Guido A Gubertini, Carlo Magni, Angela Testa, Pasquale Narciso, Giorgio Antonucci, Maria Vinci, Giovambattista Pinzello, Erika Fatta, Silvia Fargion, Paolo Del Poggio, Barbara Coco, Maurizia R Brunetto, Marco Andreoletti, Agostino Colli, Massimo Fasano, Teresa Santantonio, Guido Colloredo, Luisa Pasulo, Stefano Fagiuoli, Alberto Eraldo Colombo, Giorgio Bellati, Francesco Fumagalli Maldini, Maria Milanese, Massimo Pozzi, Natalia M Terreni, Giancarlo Spinzi, Michela Quagliuolo, Mauro Borzio, Giovanna Lunghi, Massimo Colombo
*Corresponding author: Pietro Lampertico
Division of Gastroenterology, Università degli Studi di Milano, Milan, Italy
F1000Posters 2012, 3: 613 (poster) [English]
Poster [227.07 KB] | Recommended by F1000Prime
Presented at
47th Annual International Liver Congress 2012,
18 - 22 Apr 2012, 522
This study was conducted to assess the long-term effectiveness and safety of entecavir (ETV) in a large cohort of NUC-naive patients with chronic hepatitis B.
ETV monotherapy was safe and effective for up to four years in clinical practice, providing high rates of virological suppression and increasing rates of HBeAg and HBsAg seroconversion.
No relevant competing interests disclosed.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License
